GB9828767D0 - Novel process - Google Patents

Novel process

Info

Publication number
GB9828767D0
GB9828767D0 GBGB9828767.5A GB9828767A GB9828767D0 GB 9828767 D0 GB9828767 D0 GB 9828767D0 GB 9828767 A GB9828767 A GB 9828767A GB 9828767 D0 GB9828767 D0 GB 9828767D0
Authority
GB
United Kingdom
Prior art keywords
novel process
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9828767.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9828767.5A priority Critical patent/GB9828767D0/en
Publication of GB9828767D0 publication Critical patent/GB9828767D0/en
Priority to PCT/GB1999/004358 priority patent/WO2000039090A1/en
Priority to JP2000591002A priority patent/JP2002533441A/en
Priority to AU18763/00A priority patent/AU1876300A/en
Priority to EP99962403A priority patent/EP1178962A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
GBGB9828767.5A 1998-12-29 1998-12-29 Novel process Ceased GB9828767D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9828767.5A GB9828767D0 (en) 1998-12-29 1998-12-29 Novel process
PCT/GB1999/004358 WO2000039090A1 (en) 1998-12-29 1999-12-22 Process for the preparation of paroxetine acetate and analogues thereof
JP2000591002A JP2002533441A (en) 1998-12-29 1999-12-22 Process for producing paroxetine acetate and its analogs
AU18763/00A AU1876300A (en) 1998-12-29 1999-12-22 Process for the preparation of paroxetine acetate and analogues thereof
EP99962403A EP1178962A1 (en) 1998-12-29 1999-12-22 Process for the preparation of paroxetine acetate and analogues thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828767.5A GB9828767D0 (en) 1998-12-29 1998-12-29 Novel process

Publications (1)

Publication Number Publication Date
GB9828767D0 true GB9828767D0 (en) 1999-02-17

Family

ID=10845123

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9828767.5A Ceased GB9828767D0 (en) 1998-12-29 1998-12-29 Novel process

Country Status (5)

Country Link
EP (1) EP1178962A1 (en)
JP (1) JP2002533441A (en)
AU (1) AU1876300A (en)
GB (1) GB9828767D0 (en)
WO (1) WO2000039090A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1017421C2 (en) 2001-02-21 2002-01-15 Synthon Bv Process for the production of paroxetine.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
AR001982A1 (en) * 1995-02-06 1998-01-07 Smithkline Beecham Plc PAROXETINE CHLORHYDRATE ANHYDRATED, AND PROCEDURE FOR ITS PREPARATION
HUP9900318A3 (en) * 1995-05-17 2001-09-28 Novo Nordisk As Process for preparing 4-aryl-piperidine derivatives
JP3882224B2 (en) * 1996-05-31 2007-02-14 旭硝子株式会社 Method for producing paroxetine
ID24383A (en) * 1997-05-29 2000-07-13 Smithkline Beecham Corp NEW PROCESS

Also Published As

Publication number Publication date
WO2000039090A1 (en) 2000-07-06
AU1876300A (en) 2000-07-31
JP2002533441A (en) 2002-10-08
EP1178962A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
GB0106312D0 (en) Process
GB9816385D0 (en) Process
EP1127060A4 (en) Hydroboronation process
GB9827387D0 (en) Novel process
GB9826180D0 (en) Novel process
GB9826242D0 (en) Novel process
GB9806527D0 (en) Process
GB9816564D0 (en) Process
GB9826175D0 (en) Novel process
GB9824298D0 (en) Novel process
GB9826178D0 (en) Novel process
GB9817195D0 (en) Novel process
GB9828779D0 (en) Novel process
GB9806786D0 (en) Novel process
GB9828767D0 (en) Novel process
GB9828780D0 (en) Novel process
GB9816027D0 (en) Novel process
GB9817159D0 (en) Novel process
GB9817196D0 (en) Novel process
GB9826182D0 (en) Novel process
GB9826176D0 (en) Novel process
GB9828781D0 (en) Novel process
GB9813269D0 (en) Novel process
GB9812016D0 (en) Novel process
GB9807834D0 (en) Novel process

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)